Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals has a market capitalization of $10.48 million and a price-to-book ratio of 1.15, indicating that the market values the company slightly above its book value. The company's liquidity position is characterized by a current ratio of 3.61, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's operating cash flow is negative at -$1.43 million, and its free cash flow is also negative at -$2.30 million, indicating ongoing cash outflows from operations. Profitability metrics show that Quoin Pharmaceuticals is currently unprofitable, with a net income of -$2.33 million and an operating income of -$2.46 million. The company's return on equity is -25.5%, and its return on assets is -14.43%, both significantly below the industry median for biotechnology firms. The company's debt-to-equity ratio is 0.37, which is relatively low, but its negative net cash position after subtracting total debt raises concerns about its ability to meet long-term obligations. The company's revenue concentration is not disclosed in the available data, but its geographic exposure is limited to a single jurisdiction, as no international revenue breakdown is provided. This lack of diversification could pose a risk if the company's primary market experiences regulatory or economic challenges. Looking ahead, Quoin Pharmaceuticals is expected to continue facing financial challenges. The company's operating income is projected to remain negative, and its net income is expected to show no improvement in the next fiscal year. The company's free cash flow is also expected to remain negative, indicating ongoing cash outflows from operations. These trends suggest that the company may need to secure additional financing to sustain its operations. The company's risk profile is characterized by medium liquidity risk and low dilution risk. The key financial flag is the negative net cash position after subtracting total debt, which could limit the company's ability to invest in growth opportunities. The company's dilution potential is low, as there is no indication of significant share issuance in the near term. However, the company's reliance on external financing could increase the risk of dilution in the future. Recent events include the publication of the company's latest financial results, which show continued losses and negative cash flows. The company has not disclosed any major product launches or strategic partnerships in the available data. The company's stock is currently trading at $5.81, significantly below the mean and median price targets of $29.75 and $32.50, respectively, indicating that analysts expect a substantial increase in the stock price.